Revision of the life history parameters (proportion of mature and mean weights at age) for the Iberian (south) sardine stock (ICES 8c and 9a)

Maturity and stock weights at age used in sardine assessment up to 2012 were obatined from (Portuguese and Spanish) spring acoustic surveys biological data. Following a recommendation of the WGANSA, the possible alternative use of the Daily Egg Production Method (DEPM) surveys to estimate maturity at age was evaluated, and a revision of these maturity ogives was undertaken for the last benchmark assessment (Silva et al. 2011, WKPELA 2012), the WG having decided that DEPM maturity ogives should be used in the assessment, and for years with no DEPM survey, 80% of fish mature would be assumed at age 1 (corresponding approximately to the historical mean of DEPM ogives), and for simplicity, 100% of fish are mature at age 2. But these estimates were obtained including information from both DEPM and acoustic surveys: maturity data from the DEPM for each stratum and year were combined to obtain stock estimates, using abundances at age from acoustic surveys as weighting factors; however, in most years, 1-2 months lagged between the two surveys in W and S strata. Revision of weights at age could not be carried out in 2012 due to time constraints, but the WGHANSA believes that it makes more sense that both life history parameters be derived from the same surveys. This WD describes the revision of both maturity and stock weights at age estimates, based uniquely on the DEPM surveys

DEPM 2014. Preliminary Egg Results for the Atlanto-Iberian Sardine ICES VIII and IXa

The triennial DEPM for estimation of sardine spawning biomass for the Atlanto-Iberian stock areas IXa – VIIIc and VIIIb up to 45 º N took place in the S and W (IPMA) from 15th March to 26th April and in the N (Galicia, Cantabrian Sea and French coast, IEO) between 29th March and 21st April. The whole area was surveyed however the Portuguese survey occurred much later than usual and suffered several interruptions; part of IPMA´s DEPM survey was conducted simultaneously to the acoustics survey onboard the same vessel. The number of fishing samples was maintained at levels similar to other years but it was evident that sardine schools were less available than during previous surveys in particular in the western and northern shores. Preliminary estimates highlighted a sharp decrease in egg production from 2011 to 2014; this pattern was particularly clear in the northern stratum

Pd-(L)1 inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer patients with high pd-l1 expression : A network meta-analysis

Altres ajuts: RocheProgrammed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selec-tion of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to evaluate the efficacy of first-line anti-PD-(L)1 monotherapy in advanced NSCLC patients with high PD-L1 expression (≥50%) compared to platinum-based chemotherapy. We also evaluated efficacy outcomes according to tumor mutational burden (TMB). To that end, we conducted a systematic review. Six clinical trials with 2111 patients were included. In head-to-head comparisons, immunotherapy showed a significant improvement in progression-free survival (PFS: HRpooled = 0.69, 95% CI: 0.52-0.90, p = 0.007), overall survival (OS: HRpooled = 0.69, 95% CI: 0.61-0.78; p < 0.001) and overall response rate (ORR) (Risk ratio (RR)pooled = 1.354, 95% CI: 1.04-1.762, p = 0.024). In the assessment of relative efficacy for PFS through indirect comparisons, pembrolizumab (results from KEYNOTE-024) ranked highest followed by cemiplimab and atezolizumab, with statistical significance determined for some of the drugs. In terms of OS, cemiplimab ranked highest followed by atezolizumab and pembrolizumab, although non-significant OS was determined for these drugs. In conclusion, PD-(L)1 inhibitor mon-otherapy improves efficacy outcomes in the first line setting of advanced NSCLC patients with high PD-L1 expression. Evaluations with longer follow up are still needed to determine the superiority of any specific drug